Showing results (691-700 of 719) with videos related to

Sort By:
Pageof 72
Clinical and Experimental Hepatology|September 4, 2025
Clinical characteristics and risk factors of metabolic dysfunction-associated steatotic liver disease in lean patients: results of the Polish Gallstone Surgery RegistryIwona Gorczyca-Głowacka, Łukasz Nawacki, Magdalena Kołomańska, et al.
Cardiovascular Diagnosis and Therapy|September 24, 2020
Prevalence and risk factors of left atrial thrombus in patients with atrial fibrillation and lower class (IIa) recommendation to anticoagulantsBeata Uziębło-Życzkowska, Paweł Krzesiński, Agnieszka Jurek, et al.
Orphanet Journal of Rare Diseases|April 10, 2026
Juvenile Inflammatory Rheumatism Real-Life Clinical Practice Strategies (JIR-CliPS) network: methodology and the development processHelmut Wittkowski, Raffaella Carlomagno, Sophie Georgin-Lavialle, et al.
Redox Biology|July 24, 2024
Heme oxygenase-1 protects cells from replication stressPatryk Chudy, Jakub Kochan, Mateusz Wawro, et al.
Rheumatology (Oxford, England)|June 26, 2026
Diagnostic approaches to Kawasaki disease worldwide: the results from the JIR-CliPS networkJurgita Marčiulynaitė, Daiva Gorczyca, Aušra Šnipaitienė, et al.
The Lancet. Oncology|November 17, 2018
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trialSuzanne Trudel, Nikoletta Lendvai, Rakesh Popat, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 13, 2012
The 5-hydroxytryptamine4 receptor agonists prucalopride and PRX-03140 increase acetylcholine and histamine levels in the rat prefrontal cortex and the power of stimulated hippocampal θ oscillationsDavid E Johnson, Elena Drummond, Sarah Grimwood, et al.
Leukemia & Lymphoma|October 13, 2016
Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trialTadeusz Robak, Krzysztof Warzocha, K Govind Babu, et al.
Frontiers in Pharmacology|August 1, 2020
Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic ActivationRouba Kozak, Tamás Kiss, Keith Dlugolenski, et al.
Journal of Clinical Medicine|April 3, 2021
Characteristics and Treatment of Atrial Fibrillation with Respect to the Presence or Absence of Heart Failure. Insights from the Multicenter Polish Atrial Fibrillation (POL-AF) RegistryMonika Gawałko, Monika Budnik, Iwona Gorczyca, et al.
Pageof 72